Keywords
Glucagon-like peptide 2
Sodium-glucose transporter 2 inhibitors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Analyzing the use of SGLT2i and arGLP1 in CVD. Methods: It is an integrative literature review conducted in the MEDLINE and LILACS databases via BVS and SciELO, held from February to May 2024 with the following search strategy: ("Cardiovascular Diseases" OR "Heart Failure" OR "Coronary Artery Disease") AND ((Glucagon-Like Peptide 2) AND (Sodium-Glucose Transporter 2 Inhibitors)). Results: 570 articles were found, which after the application of the inclusion and exclusion criteria, and double-blind analysis resulted in a final corpus of 22 articles. The results showed that SGLT2i reduces hospitalization due to heart failure, and arGLP1 is associated with a lower risk of unstable angina and acute myocardial infarction when compared to SGLT2i. Both classes reduce all-cause mortality, risk of major adverse cardiovascular effects, and when used concurrently, also demonstrate a beneficial cardiometabolic effect. Final considerations: Given the above, it is evident that both classes have cardioprotective effects and the results obtained in the study may contribute to evidence-based clinical practice.
References
ANKER SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 2021; 385(16): 1451–61.
BERG DD, et al. Time to Clinical Benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol, 2021; 6(5): 499–507.
BHATT DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New England Journal of Medicine, 2021; 384(2): 117–28.
BOCCHI EA, et al. Tópicos emergentes em insuficiência cardíaca: inibidores do cotransportador Sódio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros de Cardiologia, 2021; 116(2): 355-8.
CARDIÔMETRO. 2023. Indicadores atualizados de doenças cardiovasculares no Brasil. Disponível em: [http ://www.cardiometro.com.br/]. Acessado em: 21 de março de 2023.
DOS REIS MAO de M, et al. Complicações cardiovasculares em pacientes com Diabetes Mellitus Tipo 2. Revista Eletrônica Acervo Saúde, 2021; 13(3): 6426.
DUARTE R, et al. Recomendações Nacionais da SPD para o Tratamento da Hiperglicemia na Diabetes Tipo 2 -atualização 2018/19 com base na posição conjunta ADA/EASD. Revista Portuguesa de Diabetes, 2018; 13(4): 154–80.
DUNGAN KM, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet, 2014; 384(9951): 1349–57.
FERRO EG, et al. New antidiabetes medications and their cardiovascular and renal benefits. Cardiol Clin, 2021; 39(3): 335–51.
GARBER AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of theirefficacy and tolerability. Diabetes Care, 2011; 34(2): 279.
GARCIA AKA, et al. Estratégias para o alívio da sede: revisão integrativa da literatura.Revista Brasileira de Enfermagem, 2016; 69(6): 1215–22.
GERSTEIN HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 2019; 394(10193): 121–30.
HEERSPINK HJL, et al. Sodium glucose cotransporter 2 inhibitors in the treatment ofdiabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinicalapplications. Circulation, 2016; 134(10): 752–72.
HONNEF F, et al. Escolhas das mulheres no processo de parto: revisão integrativa. Ciência, Cuidado e Saúde, 2019; 18(4).
LACERDA MCRGS. Metodologias da pesquisa para enfermagem e saúde da teoria àprática. Porto Alegre: MoriáEditora LTDA, 2016; 1: 345.
LAZARINI G, et al. Isquemia miocárdica na cintilografia. Impacto da presença de diabetes em população com elevado risco cardiovascular. Rev Soc Cardiol Estado de São Paulo, 2020; 167: 167.
LEE MMY, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 2021; 143(6): 516–25.
LUDVIK B, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol, 2018; 6(5): 370–81.
MARSO SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull, 2016; 54(9): 101.
MARSO SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 2016; 375(19): 1834–44.
MCMURRAY JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 2019; 381(21): 1995–2008.
MILLER E e SHUBROOK JH. Sodium glucose co-transporter 2 inhibitors in the treatmentof type 2 diabetes mellitus. Osteopathic Family Physician, 2015; 7(5): 10–30.
MOHER D, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med, 2009; 6(7): 1000097.
MORALES J e HANDELSMAN Y. Cardiovascular outcomes in patients with diabetes andkidney disease: JACC review topic of the week. J Am Coll Cardiol, 2023; 82(2): 161–70.
NASSIF ME, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med, 2021; 27(11): 1954–60.
OPAS/OMS. 2024. Doenças cardiovasculares - OPAS/OMS | Organização Pan-Americana da Saúde. Disponível em: [https ://www.paho.org/pt/topicos/doencas-cardiovasculares]. Acessado em: 25 de abril de 2024.
PACKER M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 2020; 383(15): 1413–24.
PERKOVIC V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 2019; 380(24): 2295–306.
PRASAD-REDDY L e ISAACS D. A clinical review of GLP-1 receptor agonists: efficacyand safety in diabetes and beyond. Drugs Context, 2015; 4: 212283.
ROHDE LEP, et al. Diretriz brasileira de insuficiência cardíaca crônica e aguda. Arquivos Brasileiros de Cardiologia, 2018; 111(3): 436–539.
SANTOS CMDC, PIMENTA CADM e NOBRE MRC. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 2007; 15(3): 508–11.
SILVA GA, et al. Inibidores da SGLT2 e suas influências no sistema cardiovascular: uma revisão sistemática. Revista Eletrônica Acervo Saúde, 2020; (44): 3325.
SOUSA LS, et al. Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences, 2021; 35(1): 95–106.
SRIDHAR VS, et al. Making a case for the combined use of SGLT2 inhibitors and GLP1receptor agonists for cardiorenal protection. Jornal Brasileiro de Nefrologia, 2020; 42(4): 467.
UTHMAN L, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia, 2017; 61(3): 722.
VADUGANATHAN M, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet, 2022; 400(10354): 757–67.
VERMA S e MCMURRAY JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 2018; 61(10): 2108–17.
VIEIRA JT, et al. Caracterização clínica e epidemiológica dos usuários com diabetes mellitus: revisão integrativa. Conjecturas, 2022; 18: 1025–45.
ZOU CY, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality intype 2 diabetes: A meta-analysis. Medicine, 2019; 98(49): 18245.